EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Compound Danshen Dripping Pill inhibits hypercholesterolemia/atherosclerosis-induced heart failure in ApoE and LDLR dual deficient mice via multiple mechanisms

Yanfang Yang, Ke Feng, Liying Yuan, Yuxin Liu, Mengying Zhang, Kaimin Guo, Zequn Yin, Wenjia Wang, Shuiping Zhou, He Sun, Kaijing Yan, Xijun Yan und 4 weitere

Acta Pharmaceutica Sinica B · 2023-03 · 13 (3) · 1036-1052

DOI: 10.1016/j.apsb.2022.11.012 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Acta Pharmaceutica Sinica B, 2023-03. Verfasst von Yanfang Yang und 15 weiteren Autor:innen. Beteiligte Einrichtung: College of Life Sciences, State Key Laboratory of Medicinal Chemical Biology, Key Laboratory of Bioactive Materials of Ministry of Education, Nankai …. Die Arbeit wurde bisher 42-mal zitiert (Crossref) und nennt 60 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Ministry of Science and Technology of the People's Republic of China, Tianjin Science and Technology Committee, National Key Research and Development Program of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

Stichwörter der Autor:innen

ApoE–/–LDLR–/– miceAtherosclerosisCompound danshen dripping pillHeart failureHypercholesterolemiaInflammationOxidative stressSimvastatin

Autor:innen und Institutionen

  • College of Life Sciences, State Key Laboratory of Medicinal Chemical Biology, Key Laboratory of Bioactive Materials of Ministry of Education, Nankai University, Tianjin 300071, China.
  • Department of Physiology, Binzhou Medical University, Yantai 264003, China.
  • Cloudphar Pharmaceuticals Co., Ltd., Shenzhen 518000, China.
  • Key Laboratory of Metabolism and Regulation for Major Diseases of Anhui Higher Education Institutes, Hefei University of Technology, Hefei 230009, China.
  • The State Key Laboratory of Core Technology in Innovative Chinese Medicine, Tasly Academy, Tasly Holding Group Co., Ltd., Tianjin 300410, China.
  • Tasly Pharmaceutical Group Co., Ltd., Tianjin 300410, China.

Förderung

  • Ministry of Science and Technology of the People's Republic of China
  • Tianjin Science and Technology Committee
  • National Key Research and Development Program of China
  • Fundamental Research Funds for the Central Universities
  • National Natural Science Foundation of China

Zitieren

APA

Yang, Y., Feng, K., Yuan, L., Liu, Y., Zhang, M., Guo, K., Yin, Z., Wang, W., Zhou, S., Sun, H., Yan, K., Yan, X., Wang, X., Duan, Y., Hu, Y., & Han, J. (2023). Compound Danshen Dripping Pill inhibits hypercholesterolemia/atherosclerosis-induced heart failure in ApoE and LDLR dual deficient mice via multiple mechanisms. Acta Pharmaceutica Sinica B, 13(3), 1036-1052. https://doi.org/10.1016/j.apsb.2022.11.012

Vancouver

Yang Y, Feng K, Yuan L, Liu Y, Zhang M, Guo K, et al. Compound Danshen Dripping Pill inhibits hypercholesterolemia/atherosclerosis-induced heart failure in ApoE and LDLR dual deficient mice via multiple mechanisms. Acta Pharmaceutica Sinica B. 2023;13(3):1036-1052. doi:10.1016/j.apsb.2022.11.012

BibTeX
@article{Yang2023,
  author = {Yang, Yanfang and Feng, Ke and Yuan, Liying and Liu, Yuxin and Zhang, Mengying and Guo, Kaimin and Yin, Zequn and Wang, Wenjia and Zhou, Shuiping and Sun, He and Yan, Kaijing and Yan, Xijun and Wang, Xuerui and Duan, Yajun and Hu, Yunhui and Han, Jihong},
  title = {Compound Danshen Dripping Pill inhibits hypercholesterolemia/atherosclerosis-induced heart failure in ApoE and LDLR dual deficient mice via multiple mechanisms},
  journal = {Acta Pharmaceutica Sinica B},
  year = {2023},
  volume = {13},
  number = {3},
  pages = {1036--1052},
  doi = {10.1016/j.apsb.2022.11.012}
}
Kostenlos starten →